Don't qualify for this program? Visit the DBAs to look for financial assistance based on your diagnosis.  

Advancing Access Program

This program provides brand name medications at no or low cost

Provided by: Gilead Sciences, Inc.

PO Box 13185
La Jolla, CA 92039-3185

TEL: 800-226-2056

FAX: 800-216-6857
Languages Spoken:

English, Others By Translation Service

Program Website


Program Applications and Forms

Gilead Advancing Access Enrollment Form

Gilead Advancing Access Enrollment Form (Spanish)

Advancing Access Uninsured 24/7 Support: Contact program

HIV Common Application: Gilead Sciences Advancing Access



  • adefovir dipivoxil tablet (Hepsera) Tablet

Eligibility Requirements   

Insurance Status Must be uninsured or underinsured
Those with Part D Eligible? Contact program for details.
Income At or below 500% of FPL
Diagnosis/Medical Criteria Medically appropriate condition/diagnosis
US Residency Required? Must be residing in the US or Puerto Rico


Obtaining Call, download or apply online
Receiving Faxed or mailed
Returning Fax or mail
Doctor's Action Complete section and sign
Applicant's Action Complete section, sign, attach a copy of proof of income
Decision Communicated Patient and Doctor notified in writing
Decision Timeframe 3-5 business days


Amount/Supply Varies. *see below for details
Sent To Varies. *see below for details
Delivery Time 1-2 business days
Refill Process Patient contacts pharmacy
Limit One calendar year
Re-application Once a year new application required. Financial documentation may be requested any time

Additional Information

This program is for outpatient use only.

Co-payment assistance, reimbursement support, and patient assistance programs are available for eligible patients.

This Program participates in the CPAPA. This single common application allows uninsured HIV-positive individuals with low incomes to use one application to apply for multiple assistance programs.

IMPORTANT: Send completed CPAPA to the corresponding addresses listed for each company.

Updated March 02, 2021